COEP Historical PE Ratio Notes

— Coeptis Therapeutics Holdings, Inc. (ticker: COEP) is a clinical-stage biopharmaceutical company focused on developing innovative cell therapy and immune-oncology products for treating cancer and autoimmune diseases. Its pipeline includes unique CAR-T and NK cell-based therapies, targeting areas such as multiple myeloma and glioblastoma, which are fields with significant unmet medical need. For investors examining COEP's historical price, earnings, and PE ratio charts, it's important to understand that as an early-stage biotech, Coeptis typically reports negative earnings due to heavy R&D and low or no revenue. This often results in either a very high or undefined PE ratio (since PE ratios require positive earnings), reflecting both the speculative nature of the company ’s future prospects and market expectations for successful clinical progress or eventual product commercialization. Shifts in PE ratios—if they become defined—generally signal major changes such as the transition to profitability, positive clinical data, or a commercial launch. When analyzing COEP's historical ratios, focus on clinical milestones & product development news, as these are key drivers behind the stock market's valuation premiums or discounts over time.

On this page we presented the Coeptis Therapeutics Historical PE Ratio information for Coeptis Therapeutics' stock. The average COEP historical PE based on using the annualized quarterly earnings result at each measurement period (for the "E" in the PE calculation; and the closing price on earnings date as the "P") is NA. Meanwhile, using the trailing twelve month (TTM) quarterly earnings result as our method of calculation the "E" value at each measurement period, the average COEP historical PE based on this TTM earnings result method is NA. Note: any PE calculations involving negative earnings were discarded as not meaningful.

Let's now compare this COEP historical PE result, against the recent PE: when this page was posted on 3/31/2026, the most recent closing price for COEP had been 11.22, and the most recent quarterly earnings result, annualized, was NA. Meanwhile, the most recent TTM earnings summed to NA.

For self directed investors doing their due diligence on COEP or any other given stock, valuation analysis for COEP can greatly benefit from studying the past earnings and resulting PE calculations. This exercise can help inform an analysis as to whether the past earnings trajectory and current versus historical PE ratios justify the current stock value.

That's why we bring you HistoricalPERatio.com to make it easy for investors to investigate Coeptis Therapeutics PE history or the past PE information for any stock in our coverage universe. And in your continued research we hope you will be sure to check out the further links included for earnings surprises history (beat/miss data) as well as next earnings dates for COEP. Thanks for visiting, and the next time you need to research COEP Historical PE Ratio or the ratio for another stock, we hope you'll think of our site, as your go-to historical PE ratio research resource of choice.